News Releases & Statements
News Releases & Statements
The Leukemia & Lymphoma Society (LLS) Named Charitable Partner of Largest Esports League in North America
Posted On: September 9, 2021 Read More
Every 180 Seconds, Someone in the U.S. is Diagnosed with a Blood Cancer; it’s Time to Make an Impact Together
Posted On: September 1, 2021(Rye Brook, NY, Sept. 1, 2021) — September is Blood Cancer Awareness Month, an opportunity to remind the public that every 180 seconds, someone in the U.S. has their life turned upside down by a blood cancer diagnosis. Read More
New COVID-19 Staff Safety Policies at LLS
Posted On: August 16, 2021The following memo from Louis J. DeGennaro, Ph.D., President and Chief Executive Officer of The Leukemia & Lymphoma Society (LLS), was shared with LLS staff on Tuesday, 8/17. The email has been edited to remove internal links.
Read More
FDA Approves New Treatment Option for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Posted On: August 10, 2021Rye Brook, NY, August 10, 2021 - The U.S. Food and Drug Administration (FDA) approved loncastuximab tesirine-lpyl (ZYNLONTA) to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more earlier treatments with systemic therapy including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma.
Read More
FDA Approves New Treatment Option For Chronic Graft-Versus-Host-Disease In Patients Ages 12 Years And Older
Posted On: August 3, 2021
Rye Brook, N.Y., August 3, 2021 - The U.S. Food and Drug Administration (FDA) recently approved belumosudil (Rezurock™) in patients 12 years or older for the treatment chronic graft-versus-host-disease (GvHD) that has not responded or has stopped responding to earlier treatments.
Read More
FDA Approval: New Treatment Indication for Multiple Myeloma Drug
Posted On: August 3, 2021Rye Brook, N.Y., August 3, 2021 - The U.S. Read More
LLS Urges Blood Cancer Patients to get Vaccinated as its National Patient Registry Enters Next Phase in COVID-19 Vaccine Studies
Posted On: July 15, 2021Rye Brook, N.Y., July 15, 2021—The Leukemia & Lymphoma Society® (LLS) began recruitment this week for a new study evaluating T-cell immune response to COVID-19 vaccine among people with a current or past diagnosis of blood cancer. This invitation-only follow-up study will include a sub-set of participants from a larger LLS study examining COVID-19 spike antibody response to vaccination. Both studies are being conducted as part of the LLS National Patient Registry, a project of the Michael J. Garil Patient Data Collective.
Read MoreMedia Requests
Please send all media-related inquiries and interview requests to mediarelations@lls.org. An LLS representative will respond as soon as possible.